Researchers concerned over early egg retrieval after cancer treatment - doctors advised to monitor pregnancies as mice study reveals problems

An international team of fertility experts is asking doctors to monitor carefully the pregnancies and babies of all women who undergo egg retrieval and IVF after cancer chemotherapy.

Research on mice has shown that cylophosphamide - a commonly used drug belonging to a group of anti-cancer agents known as alkylating agents - causes fetal malformations and pregnancy failure. More importantly, the new study reveals that the effect on the embryo is influenced by the stage of egg follicle development at the time of exposure to the drug.

Although the researchers stress that there is no evidence as yet to suggest equivalent treatment-induced problems in human eggs, they believe that their findings indicate that eggs collected from women within six to 12 months of treatment could be particularly vulnerable to damage.

The study has been carried out by Dr Dror Meirow at the Rabin Medical Centre and Schneider Children Medical Centre in Israel, Drs Michal Epstein and Hadassa Lewis at the Hadassah Medical Centre in Jerusalem, Dr David Nugent at the University of Leeds in the UK, and Professor Roger Gosden at the Royal Victoria Hospital, Montreal, Canada.

The results are reported today* (Thursday 29 March) in Europe's leading fertility journal, Human Reproduction.

Although research has already shown that cyclophosphamide can induce genetic damage and has raised concerns about pregnancies in cancer survivors and the health of the children, all the studies on pregnancy outcome to date have been reassuring, suggesting that these concerns are unfounded. However, the research was on women who became pregnant a long time after treatment stopped.

New reproductive techniques mean that many centres offer egg retrieval and embryo freezing before starting cancer treatment that is likely to result in infertility. But delaying life-saving treatment while patients undergo egg-retrieval cycles may be inadvisable. So some centres now offer IVF and embryo cryopreser

Contact: Margaret Willson
44-0-1536 772181
European Society for Human Reproduction and Embryology

Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:

(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman ... AngelList early in their initial angel funding process. Now, they are paying it ... to make early stage investments in the microbiome space. In this, they ...
Breaking Biology Technology:
Cached News: